Today, the Access to Advanced Health Institute (AAHI) is pleased to announce that its unique adjuvant formulations are included in the National Institute of Health’s Vaccine Adjuvant Compendium (VAC), a reference guide to the characteristics and performance of specific adjuvant formulations for vaccine developers to perfectly match the appropriate adjuvant formulation with their antigen. Adjuvants are not a one-size-fits-all solution to enhancing immune responses and the VAC allows developers to understand the differences of various formulations to select one that maximizes the impact of their specific vaccine candidate.
AAHI’s formulations are optimized to elicit a combination of T-cells and antibodies for broader and more durable protection against target pathogens. With one of the largest adjuvant portfolios in the world, AAHI’s adjuvant formulations have been extensively tested in human clinical trials over the last several decades with a proven safety record. We are uniquely positioned to provide custom formulation services, ensure drug product stability, supply research and cGMP-grade material for preclinical Phase 1/ 2 clinical trials, and assist with FDA and other regulatory agency submissions and clinical trial support. Visit AAHI’s adjuvant portfolio that includes the VAC profiles to identify the adjuvant formulation that may be most suited to your purpose.
About Vaccine Adjuvant Compendium (VAC) The Vaccine Adjuvant Compendium (VAC) was established in 2020 by the NIAID Division of Allergy, Immunology, and Transplantation to foster collaborations between NIAID-supported adjuvant researchers and the broader scientific community. The VAC displays adjuvant characteristics or metadata defined through NIAID-supported adjuvant studies to help vaccine developers identify suitable adjuvants for various vaccine indications, including immune-mediated and infectious diseases. In addition, the VAC welcomes the inclusion of adjuvant metadata generated by other research programs.
AAHI is a nonprofit biotech research institute located in Seattle, Washington that combines the high-quality science of an academic research organization with the product-development capabilities of a biotech company to help combat some of the world’s deadliest diseases, including COVID-19, cancer, fungal and parasitic infections, and other non-communicable diseases. For nearly three decades, AAHI, previously known as the Infectious Disease Research Institute, has focused on creating immune-enhancing technologies that improve the body’s natural response to disease. Through collaborations AAHI brings innovation from the lab to the clinic to the people, furthering AAHI’s mission to bring together the best experts, technologies, and platforms to create accessible, high-quality products, and solutions. AAHI is working to build a world in which every person has access to tools that harness their immune system and allow them to live a healthy life free of illness and disease. For more information, go to AAHI.org or follow us on LinkedIn.